Company Insight – Page 17 – media

mHealth Tools, AI Combine to Avert Serious Diabetic Health Issues

mHealth tools embedded with AI technology are helping doctors and those living with diabetes detect hyperglycemia and hypoglycemia up to an hour ahead of time, averting serious and potentially fatal health issues.
- Source: drugdu
- 1,253
- March 19, 2018
AI Company Insight digital health mHealth
GlaxoSmithKline chief Emma Walmsley nets $6.8M in pay in her first year at the helm

Investors who pressed GlaxoSmithKline to slash new CEO Emma Walmsley’s pay package before she took the helm probably won’t much like her overall compensation figure for 2017.
- Source: fiercepharma
- 560
- March 16, 2018
Company Insight GSK
Boehringer, Vanderbilt U to develop cancer MCL1 inhibitors in third team-up

Cancer cells are different from normal cells in that they can avoid a naturally programmed cell death process known as apoptosis and grow almost indefinitely. In their third collaboration, Boehringer Ingelheim and Vanderbilt University have their eyes on a target that helps cancer cells evade death.
- Source: fiercebiotech
- 457
- March 16, 2018
apoptosis Company Insight MCL1
Takeda looks east for another Entyvio growth spurt

Takeda's inflammatory bowel disease treatment Entyvio has already been delivering blockbuster-plus sales, and the Japanese drugmaker sees fertile territory for more growth in the Asia-Pacific region.
- Source: fiercepharma
- 523
- March 15, 2018
bowel Company Insight Entyvio
Patient death forces FDA to slap a hold on study using combo from Advaxis, AstraZeneca — biotech’s shares plunge

The FDA has slapped a clinical hold on a combo therapy using Advaxis’$ADXS axalimogene filolisbac along with AstraZeneca’s approved PD-L1 Imfinzi following the death of a patient in their Phase I/II trial.
- Source: endpts
- 633
- March 15, 2018
AstraZeneca cervical cancer Company Insight FDA
IMMUTEP ENTERS INTO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MSD

Immutep Limited (ASX:IMM) (IMMP) (“Immutep” or the “Company”) has announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a new clinical trial that will evaluate the combination in several different solid tumours.
- Source: finance.yahoo
- 637
- March 14, 2018
Company Insight immunotherapy keytruda
Fitbit unveils new tracker for kids, new smartwatch for adults

Come this spring adults won’t be the only ones with their own line of Fitbit trackers. The company recently announced a new set of products including the Fitbit Ace, which is a tracker designed for children 8 years old and up, as well a much anticipated new smartwatch, the Fitbit Versa.
- Source: MobiHealthNews
- 595
- March 14, 2018
Company Insight digital health Fitbit wearables
Biogen buys Pfizer’s unwanted neuro med for $75M as sell-off starts

As Pfizer clears house of its unwanted neuro assets, Biogen has become a buyer for one, namely a phase 2-ready schizophrenia drug.
- Source: FierceBiotech
- 770
- March 13, 2018
Company Insight Pfizer pharmaceutical schizophrenia
Science 37 and Novartis Sign Strategic Alliance to Advance Decentralized Clinical Trials

Science 37, a trailblazing company focused on “site-less” clinical trials, announced today a strategic alliance with Novartis that will support the development of its new decentralized clinical trial (DCT) offerings. This three-year commitment will enable a more extensive portfolio of trials powered by the Network Oriented Research Assistant (NORA®), Science 37’s proprietary technology platform that enables patients to participate in clinical research regardless of their geographical location using mobile devices and telemedicine services.
- Source: Science 37
- 576
- March 12, 2018
Company Insight digital health Novartis
J&J CIO touches on FDA pre-cert pilot program, artificial intelligence and innovation

Stuart McGuigan took on his role as CIO of industry behemoth Johnson & Johnson in 2012. That was around the same time that Alex Gorsky joined the company as CEO. Since then, part of Gorsky’s mission has been to help J&J focus on technology, McGuigan said in an interview at HIMSS this week.
- Source: MedCityNews
- 688
- March 9, 2018
AI Company Insight healthcare technologies and innovations

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.